A Case-Based Review on the Diagnosis and Treatment Options for Recurrent Wheezing and Asthma in Preschool Children
- 2 Downloads
Purpose of review
To summarize the recent evidence on the various wheezing patterns in early life and provide a case-based review with insights into clinical application of individualized therapy in preschool children with recurrent wheezing.
Preschool wheezing is often characterized predominantly by the risk domain with exacerbations and relatively limited impairment. In children with intermittent disease and a positive Modified Asthma Predictive Index, intermittent therapy with inhaled corticosteroids (ICSs) should be considered as an initial therapy to prevent exacerbations. Early administration of azithromycin at the onset of lower respiratory tract infections (LRTIs) reduces the risks of progression to severe illnesses in children who have a history of recurrent severe LRTIs, and more information is needed regarding the risks of developing drug-resistant organisms. In preschool children with mild persistent asthma, allergic sensitization to aeroallergens and absolute eosinophil count can help identify children most likely to have a good response to daily ICS.
Recent clinical trials in preschool children with severe episodic wheezing and persistent asthma have made a significant impact on the approach for the care of these children, particularly with evidence directing individualized approaches based on specific clinical features and biomarkers.
KeywordsRecurrent wheezing Preschool Asthma Phenotypes
Compliance with ethical standards
Conflict of interest
Leonard Bacharier reports personal fees from Aerocrine, personal fees from GlaxoSmithKline, personal fees from Genentech/Novartis, personal fees from Merck, personal fees from DBV Technologies, personal fees from Teva, personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, personal fees from WebMD/Medscape, personal fees from Sanofi/Regeneron, personal fees from Vectura, and personal fees from Circassia outside the submitted work. Maleewan Kitcharoensakkul declares no conflicts of interest relevant to this manuscript.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.• Fitzpatrick AM, Bacharier LB, Guilbert TW, Jackson DJ, Szefler SJ, Beigelman A, et al. Phenotypes of recurrent wheezing in preschool children: identification by latent class analysis and utility in prediction of future exacerbation. J Allergy Clin Immunol Pract. 2019;7(3):915–24 e7. This article showed sensitization and exposure assessments are useful predictors of future exacerbation in children aged 12 to 71 months.CrossRefGoogle Scholar
- 4.Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, et al. National surveillance of asthma: United States, 2001–2010. Vital Health Stat 3. 2012;35:1–58.Google Scholar
- 11.Biagini Myers JM, Schauberger E, He H, Martin LJ, Kroner J, Hill GM, et al. A Pediatric Asthma Risk Score to better predict asthma development in young children. J Allergy Clin Immunol. 2018.Google Scholar
- 15.2019 Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed 13 July 2019.
- 27.• Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: a systematic review. Pediatr Pulmonol. 2018;53(12):1670–7. The article demonstrated daily inhaled corticosteroids is more effective than daily montelukast for improving asthma control and decreasing exacerbations in preschool children.CrossRefGoogle Scholar
- 28.• Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608-18 e12. The majority of preschool children with mild persistent asthma had differential responses to either daily ICS, daily LTRA or symptom-driven ICS treatment. Aeroallergen sensitization and blood eosinophil counts are useful to identify children who will most likely have a good response to daily ICS.Google Scholar
- 29.Depner M, Fuchs O, Genuneit J, Karvonen AM, Hyvarinen A, Kaulek V, et al. Clinical and epidemiologic phenotypes of childhood asthma. Am J Respir Crit Care Med. 2014;189(2):129–38.Google Scholar
- 30.• Kaiser SV, Huynh T, Bacharier LB, Rosenthal JL, Bakel LA, Parkin PC, et al. Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis. Pediatrics. 2016;137(6). The article emphasized the efficacy of daily ICS to prevent exacerbations in preschool children with persistent asthma and of intermittent ICS to prevent exacerbations in children with intermittent diseases.Google Scholar
- 33.Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008;122(6):1127–35 e8.CrossRefGoogle Scholar
- 42.• Hussein HR, Gupta A, Broughton S, Ruiz G, Brathwaite N, Bossley CJ. A meta-analysis of montelukast for recurrent wheeze in preschool children. Eur J Pediatr. 2017;176(7):963–9. The meta-analysis found montelukast was ineffective in reducing oral corticosteroid uses for preschool wheeze.CrossRefGoogle Scholar
- 48.• Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA. 2015;314(19):2034–44. The article demonstrated the early use of azithromycin during an apparent lower respiratory tract illnesses reduced the likelihood of severe LRTI in young children with histories of recurrent severe RTI, compared to placebo.CrossRefGoogle Scholar